Chemocentryx reported $345.17M in Current Assets for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Alnylam Pharmaceuticals ALNY:US $ 2471.64M 118.04M
Amgen AMGN:US $ 19322M 802M
AstraZeneca AZN:LN 20.92B 1.73B
Bayer BAYN:GR 39.55B 1.3B
Biogen BIIB:US $ 9740.9M 1825M
Biomarin Pharmaceutical BMRN:US $ 2517.6M 123.57M
Bristol Myers Squibb BMY:US $ 30186M 65M
Chemocentryx CCXI:US $ 345.17M 6.46M
GlaxoSmithKline GSK:LN 5418.8B 2520B
Glaxosmithkline GSK:US $ 54188M 25200M
Macrogenics MGNX:US $ 167.63M 50.57M
Mirati Therapeutics MRTX:US $ 1202.93M 140.19M
Novartis NOVN:VX 38.14B 906M
Omeros OMER:US $ 192.72M 17.5M
Sarepta Therapeutics SRPT:US $ 2469.3M 61.65M
Takeda 4502:JP Y 2549515M 44127M
Teva Pharmaceutical TEVA:IT 12.16B 287M
YTE INCY:US $ 3625.84M 337.75M